The logic behind U.S. president Donald Trump's proposal that Canada and other countries have been “free-riding” off high prices in the United States is bizarre at best.
How a technology born from finance – the blockchain – can help the pharmaceutical industry to carry out clinical trials that protect patients.
The Saint Regis Mohawk tribe has struck a multimillion-dollar deal with Allergan. But the deal may do more harm than good.
Your guide to a public health crisis that's likely to get worse.
How can we fight the opioid epidemic? Redesign the drugs, rethink how we assess patients and mandate prescription monitoring.
Drug prices in Australia are three times higher than in New Zealand. A key reason is the lack of transparency about taxpayer subsidies for Big Pharma and the companies' own finances.
In an era when opinion often trumps evidence in public health issues, it's time to support and invest in evidence-based medicine to protect the public from dangerous, poorly informed beliefs.
The state of Ohio filed a lawsuit against opioid manufacturers. Will their legal arguments hold up in court – and what will it mean for other cities and states going after big pharma?
Drug companies funded more than 116,000 educational events for doctors over four years. Now you can find out exactly which companies footed the bills and how much they paid.
More of us are labelled as sick with the constantly changing diagnostic cut-offs for diseases. Now an international expert panel has drafted a list of things to consider before setting new thresholds.
Intuitively, it might seem desirable to speed up access to medicines. But this means more drugs will be approved that may subsequently prove unsafe or ineffective.
We have barely begun to tap into the pharmaceutical potential of the most diverse animals of all.
Children's cancer is a rare disease, which means the market is small and pharmaceutical companies have few incentives to develop drugs for these cancers.
The maker of the EpiPen has raised the price of two injectable treatments to about US$600, six times the price nine years ago. Why do drug companies do this? Because they can. The FDA ends up helping.
Feel-good fudges designed to boost staff morale are giving way to tangible projects which can be reported to shareholders.
An important new study in the United States has found doctors who receive just one cheap meal from a drug company tend to prescribe a lot more of that company's products.
What will happen to immigration, wages and the economy has been discussed at length. But the price of drugs may also be affected.
The sources of the opioid epidemic are complex, but one powerful motivator has been the pursuit of profit.
The lack of transparency and accountability found in the hedge fund world is increasingly finding a home in the pharmaceutical sector, where more people care.
Tighter regulations of medicines and devices have prevented countless deaths and disabilities. But regulation can't always protect us from harm.